Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Cancers × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 431 Carcinoma, Non-Small-Cell Lung 391 Prostatic Neoplasms 267 Lung Neoplasms 157 Stomach Neoplasms 125 Neoplasms 101 Squamous Cell Carcinoma of Head and Neck 98 Neoplasm Metastasis 84 Head and Neck Neoplasms 82 Esophageal Neoplasms 66 Ovarian Neoplasms 52 Urinary Bladder Neoplasms 39 Pancreatic Neoplasms 37 Nasopharyngeal Carcinoma 36 Sarcoma 35 Triple Negative Breast Neoplasms 28 Carcinoma, Squamous Cell 28 Carcinoma, Ovarian Epithelial 25 Adenocarcinoma of Lung 25 Adenocarcinoma 25 Esophageal Squamous Cell Carcinoma 23 Adenocarcinoma Of Esophagus 23 Carcinoma, Transitional Cell 22 Recurrence 20 Fallopian Tube Neoplasms 19 Breast Neoplasms, Male 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Melanoma 17 Carcinoma 17 Unspecified Adult Solid Tumor, Protocol Specific 16

Interventions

pembrolizumab 1 Sirolimus 1 Nivolumab 1 Ipilimumab 1 Docetaxel 1 Albumin-Bound Paclitaxel 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01019941 2010-12-16

126ASC08Q

Chong Kun Dang Pharmaceutical

Phase 1 Completed

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡